Table 2 Association between SMARCA4 and SMARCA2 mRNA expression and clinicopathological factors in the renal clear cell carcinoma dataset from TCGA.

From: High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer

Factor

SMARCA4 expression

SMARCA2 expression

High expressiona

n = 54

Lower expressionb

n = 479

P value

High expressiona

n = 54

Lower expressionb

n = 479

P value

Age

58.48 ± 11.0

60.84 ± 12.2

0.15c

57.6

60.9

0.06c

Gender

  

0.037 d

  

0.99d

 Male

28 (51.9%)

317 (66.2%)

 

35 (64.8%)

310 (64.7%)

 

 Female

26 (48.1%)

162 (33.8%)

 

19 (35.2%)

169 (35.3%)

 

Tumor stage

  

0.16d

  

0.028 d

 T1 + T2

30 (55.6%)

312 (65.1%)

 

42 (75.9%)

300 (62.6%)

 

 T3 + T4

24 (44.4%)

167 (34.9%)

 

12 (24.1%)

179 (37.4%)

 

Tumor stage (S)

  

0.076d

  

0.019 d

 SI + SII

27 (50.0%)

297 (62.4%)

 

41 (75.9%)

283 (59.5%)

 

 SIII + SIV

27 (50.0%)

179 (37.6%)

 

13 (24.1%)

193 (40.5%)

 

Lymph node metastasis

  

0.035 d

  

0.06d

 N0

30 (85.7%)

209 (95.0%)

 

26 (92.9%)

213 (93.8%)

 

 N1

5 (14.3%)

11 (5.0%)

 

2 (7.1%)

14 (6.2%)

 

Metastasis Stage Code

  

0.0009 d

  

0.24d

 M0

34 (68.0%)

387 (86.0%)

 

45 (86.5%)

376 (83.9%)

 

 M1

16 (32.0%)

63 (14.0%)

 

7 (13.5%)

72 (16.1%)

 

Histologic grade

  

0.043 d

  

0.008 d

 G1 + G2

17 (32.7%)

224 (47.5%)

 

33 (63.5%)

209 (44.2%)

 

 G3 + G4

35 (66.0%)

248 (52.5%)

 

19 (36.5%)

264 (55.8%)

 
  1. aDecile of the tumor population with higher levels of SMARCA4 or SMARCA2 mRNA.
  2. bRest of the tumors not included in the high expression decile.
  3. cStudent’s t-test.
  4. dChi-square test. Significant P values (P ≤ 0.05) are depicted in bold.
Back to article page